News Flash 12.24
At the beginning of December, the Food and Drug Administration approved Durvalumab (Imfinzi) – an immunotherapy drug – for the treatment of patients with limited stage small cell lung cancer, whose disease has not progressed following combined chemotherapy and radiotherapy regimen. Until recently, Durvalumab has been approved for small cell lung cancer patients with extensive […]
News Flash 9.2024
In the middle of September, the Food and Drug Administration (FDA) approved treatment with Ribociclib (Kisqali), combined with hormonal therapy, also for early stage breast cancer patients with hormone receptor-positive HER2-negative tumors who have undergone surgery and are at high risk of recurrence (i.e. either with lymph node involvement, or if there is no nodal […]